Business Context and Reporting Period
This Form 8-K is a current report filed by TenX Keane Acquisition (not Citius Oncology, Inc.) on December 6, 2022. The registrant is a Cayman Islands corporation and an emerging growth company. The report details a corporate action regarding the separation of its securities for trading purposes.
Key Financial Metrics
This filing is a notification of a corporate event (Item 8.01) and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The material change reported is the commencement of separate trading for the Company's securities:
- Event: Holders of Units may elect to separately trade the ordinary shares and rights included in the Units.
- Effective Date: Commencing on or about December 8, 2022.
- Trading Symbols:
- Ordinary Shares: TENK
- Rights: TENKR
- Units (if not separated): TENKU
- Exchange: Nasdaq Global Market.
- Procedure: Unit holders must contact their brokers to instruct the transfer agent (American Stock Transfer & Trust Company) to separate the Units.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future performance, or specific risk factors beyond the operational requirement for shareholders to initiate the separation process through their brokers. The Company issued a press release (Exhibit 99.1) regarding this separation, which is incorporated by reference.
Investor Verification Checklist
- Verify the correct registrant name is TenX Keane Acquisition, not Citius Oncology, Inc.
- Confirm the effective date for separate trading is on or about December 8, 2022.
- Check with your broker regarding the specific instructions required to separate Units into TENK and TENKR.
- Review the attached press release (Exhibit 99.1) for any additional details on the separation process.